HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

DCC-2036

structure in first source

Networked: 8 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - DCC-2036: 8

Experts

1.	Druker, Brian J: 3 articles (11/2011 - 01/2011)
2.	Eide, Christopher A: 3 articles (11/2011 - 01/2011)
3.	O'Hare, Thomas: 3 articles (11/2011 - 01/2011)
4.	Shen, Yingying: 2 articles (01/2019 - 01/2013)
5.	Adrian, Lauren T: 2 articles (11/2011 - 05/2011)
6.	Deininger, Michael W N: 2 articles (05/2011 - 01/2011)
7.	Flynn, Daniel L: 2 articles (05/2011 - 04/2011)
8.	Petillo, Peter A: 2 articles (05/2011 - 04/2011)
9.	Smith, Bryan D: 2 articles (05/2011 - 04/2011)
10.	Wise, Scott C: 2 articles (05/2011 - 04/2011)

Related Diseases

1.	Osteoarthritis 05/01/2023 - "The Bcr-Abl inhibitor DCC-2036 inhibits necroptosis and ameliorates osteoarthritis by targeting RIPK1 and RIPK3 kinases."
2.	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/01/2013 - "DCC-2036 has been synthesized as a third-generation TKI to combat especially the Bcr-Abl T315I mutant in chronic myeloid leukemia. " 05/01/2011 - "The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile." 11/10/2011 - "The additional approved ABL tyrosine kinase inhibitors (TKIs) nilotinib and dasatinib, along with investigational TKIs such as ponatinib (AP24534) and DCC-2036, support the possibility that mutation-mediated resistance in chronic myeloid leukemia can be fully controlled; however, the molecular events underlying resistance in patients lacking BCR-ABL point mutations are largely unknown. "
3.	Triple Negative Breast Neoplasms 01/01/2022 - "Inhibitory effect of the novel tyrosine kinase inhibitor DCC-2036 on triple-negative breast cancer stem cells through AXL-KLF5 positive feedback loop." 01/01/2019 - "Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET."
4.	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 04/12/2011 - "DCC-2036 inhibits BCR-ABL1(T315I)-expressing cell lines, prolongs survival in mouse models of T315I mutant CML and B-lymphoblastic leukemia, and inhibits primary patient leukemia cells expressing T315I in vitro and in vivo, supporting its clinical development in TKI-resistant Ph(+) leukemia."
5.	Disease Progression 01/15/2011 - "We provide an up-to-date synopsis of BCR-ABL signaling pathways, highlight new findings on mechanisms underlying BCR-ABL mutation acquisition and disease progression, discuss the use of nilotinib and dasatinib in a first-line capacity, and evaluate ponatinib, DCC-2036, and other ABL kinase inhibitors with activity against BCR-ABL(T315I) in the development pipeline."

Related Drugs and Biologics

1.	Phosphotransferases (Kinase)
2.	Tyrosine Kinase Inhibitors
3.	Dasatinib (BMS 354825)
4.	ponatinib
5.	nilotinib